Biohaven Ltd. Common Shares (BHVN) Stock Analysis — Latest Investor Quotes & Trade Calls

All In on Biohaven Trade Call

+13.26%final return

"We've gone uh all in on uh Biohaven along BHVN. This is a biotech company that got bad news today. But personally, I don't really think it was that bad news because they had this drug that they were going to try to get approval for, but it doesn't really work. So, the FDA rejected it, but most people thought it was going to get rejected. I don't think too many people thought it was going to be approved, but the stock is acting like it was their most important drug, which it most certainly is not. So, I kind of like it. In fact, I put a ton in my portfolio."

The speaker expresses a bullish stance on Biohaven (BHVN) despite recent FDA rejection of a drug, arguing that the market overreacted to the news. He emphasizes that the drug isn't central to the business and has consequently taken an aggressive buy position in his portfolio.

Low-Conviction Biohaven Buy with Potential Doubling

"I bought a little Biohaven. I bought a new drugtock. I mentioned it in Goodell. I'm not saying it's like high conviction just yet, but if you want to join Godell, you can check out what it is. Little biotech company. I think, you know, it could double."

Martin reveals that he has initiated a small position in Biohaven (assumed ticker BHVN) suggesting a potential doubling in value, although he qualifies the move as low conviction.